About: Bhavneesh Sharma

Bhavneesh Sharma

Top 20 Ranking (28.2% Avg Return) --TipRanks

Bhavneesh Sharma is a contributing analyst at FATRADER where he covers biotechnology and pharmaceuticals. A market expert with a medical degree and MBA, he is ranked among the top 15 financial bloggers and top 100 overall financial experts (including Wall Street analysts) on TipRanks.

Bhavneesh holds a Master of Business Administration degree with specialization in finance and financial markets from New York University's Stern School of Business, ranked among top 3 finance MBAs in the country. He has authored several highly-cited peer reviewed scientific publications and was awarded the Young Investigator Award at the international level twice by the American Chest Foundation and American College of Chest Physicians.

Bhavneesh's main strategy is event-driven, covering companies with near-term catalysts like data releases, PDUFA, etc. He capitalizes on his years of clinical and research experience with financial expertise (DCF modeling, etc.) to find profitable event-driven investments in the volatile U.S. biotech/pharma sector.

Successful picks have included Juno Therapeutics (picked after clinical hold), Alnylam Pharmaceuticals (picked after clinical hold), Dynavax (doubled after CRL), Neurocrine Biosciences, Sage Therapeutics, Sarepta Therapeutics (picked after negative Adcom), Zogenix, Editas medicine, Teva Pharmaceuticals (picked after the drop below $15), Tobira Therapeutics (picked after trial failure, etc.). Tobira and Juno went on to be acquired.

He is also a registered financial adviser and widely followed contributor to Seeking Alpha and SumZero.

Story Archive

Breaking News Analysis: Apple Watch's Results in Screening for Atrial Fibrillation

Apple (AAPL) announced results of a large study that used Apple Watch to screen for atrial fibrillation, a common arrhythmia.
by Bhavneesh Sharma - 3 days ago

HOT OFF THE PRESS: Insights from the annual Cowen Healthcare conference for Monday

Notes on Wave Sciences (WVE), Moderna Therapeutics (MRNA), Insmed (INSM), Magenta Therapeutics (MGTA), and Axovant Gene Therapies (AXGT).
by Bhavneesh Sharma - 1 week ago


Invitae: The 'Amazon of Genetics' and a $22 billion market opportunity

Invitae (NYSE: NVTA) is a leading genetics company which is aiming to bring foster, affordable and high-quality genetic testing to millions of people for various health conditions.
by Bhavneesh Sharma - 2 weeks ago


Cerus Corporation: A Leader In Blood Product Pathogen Reduction With A Huge Upcoming Catalyst

Analysis of Cerus Corporation (NASDAQ: CERS), engaged in the field of blood transfusion safety.
by Bhavneesh Sharma - 3 weeks ago


How To Profit From The AdCom For KPTI's Selinexor

An FDA Advisory Committee (AdCom) meeting in a few weeks to discuss tSelinexor presents potential trading opportunities in Karyopharm Therapeutics (KPTI).
by Bhavneesh Sharma - 1 month ago

Sign Up Now - Free 15-Day Trial! Go! Fatty!